xCELLigence RTCA eSight实时活细胞成像仪-类器官培养

特性

将基于阻抗的无标记 xCELLigence 实时细胞分析技术与具有红绿蓝（5x、10x 和 20x 物镜）三色荧光的活细胞成像技术相结合，增强对细胞分析及其结论的信心
全孔成像扩展：在进行 QC 或定量和监测细胞生长时可观察整个孔的情况
信息丰富的多重检测在同一个孔中结合细胞阻抗和成像，所有操作都可以在培养箱内完成
无论是 2D 还是 3D 细胞培养，都可以通过简单的工作流程提供生理相关的数据，该工作流程能够适应不同的实验方案，可同时监测细胞活力、细胞行为、细胞功能
灵活的活细胞成像，支持明场、三个荧光通道、多种孔板形式（6、12、24、48、96 或 384 孔）和容器类型（35 或 60 mm 培养皿），以及用户自定义实验流程
分析细胞数量、增殖、细胞大小/形状、形态变化和细胞-基底粘附强度的连续读数结果

技术

工作原理

应用

资料库

重要资料

Download Literature

Download a product brochure or data sheet

产品样本
English
2021 年 11 月 23 日
72.95 KB
PDF

应用简报

文献转载

产品样本

宣传单页

挂图

性能指标

技术概述

技术支持

常见问题解答

实时细胞分析 — FAQ

有关实时细胞分析和 xCELLigence 工作原理的常见问题解答

现场准备清单

用户手册

说明书

找不到您需要的内容？请联系支持团队。

Seahorse 实时细胞代谢分析支持联系信息

工具

xCELLigence RTCA eSight — 成像和阻抗客户评论

查看客户对本产品的评论，或写下您的评论

Dr. Zelia Geouveia

Institut Curie

We are a laboratory working in cancer research, namely chimeric antigen receptor (CAR)-T cells targeting different antigens in the tumor. We were seeking a high throughput platform that would allow us to evaluate CAR-T cells killing in real-time. We were also interested in visualizing the killing in real time. The xCELLigence RTCA eSight was one of the technologies that could provide such information using impedance and live cell imaging (one machine, two different and precious information). When compared with other instruments that could provide imaging information only, the image quality was similar but we would not have the impedance for comparison. Thus, we decided that having both

返回页首

视频

培训与活动

In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme

Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found a strong correlation between granzyme B secretion and dBTE-induced cytolysis of specific and nonspecific tumors. We down-selected dBTE PB01-forward based on lower cytokine induction profile and highest activation specificity. In vivo, dBTE PB01-forward demonstrated an improved half-life versus intravenous recombinant BTE delivery. In an orthotopic glioblastoma model, dBTE PB01-forward controlled tumor growth, improving animal survival, supporting the hypothesis that the blood-brain barrier does not affect the function of systemically delivered dBTE. Further study of PB01-forward for targeting glioblastoma and other IL-13Ra2+ cancers is warranted.

网络研讨会/培训

Using Impedance in Microbiology: Applications in Biofilm Research, Discovery of Novel Antimicrobials, and Selection of Antibiotic Treatments

Regulatory agencies set thresholds for volatile organic compounds (VOCs). Learn about GC/MS with purge & trap for VOC analysis to requirements of EPA 8260 & EPA 524.2.

网络研讨会/培训

Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy

Explore rapid generation of non-activated CAR T cells with enhanced potency for cancer immunotherapy in this on-demand webinar from Agilent.

网络研讨会/培训

新闻

Agilent xCELLigence RTCA 仪器助力 FDA 新批准疗法的效价测定程序开发

Agilent xCELLigence 实时细胞分析 (RTCA) 技术为 Autolus Therapeutics 公司最近获批的 CAR-T 疗法 AUCATZYL 提供了精准可靠的测试支持，有力推动了效价测定程序的开发与应用。安捷伦通过提供准确可靠的细胞分析技术，帮助 Autolus 建立了强大的分析方法。

2025 年 7 月 15 日

精选

xCELLigence RTCA eSight - 成像和阻抗

产品详细信息

Download Literature

实时细胞分析 — FAQ

找不到您需要的内容？请联系支持团队。

xCELLigence RTCA eSight — 成像和阻抗客户评论

安捷伦细胞分析出版物数据库

安捷伦细胞分析网络研讨会

Dr. Zelia Geouveia

视频

In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme

Using Impedance in Microbiology: Applications in Biofilm Research, Discovery of Novel Antimicrobials, and Selection of Antibiotic Treatments

Regulatory agencies set thresholds for volatile organic compounds (VOCs). Learn about GC/MS with purge & trap for VOC analysis to requirements of EPA 8260 & EPA 524.2.

Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy

Explore rapid generation of non-activated CAR T cells with enhanced potency for cancer immunotherapy in this on-demand webinar from Agilent.

Agilent xCELLigence RTCA 仪器助力 FDA 新批准疗法的效价测定程序开发

客户还浏览了这些产品